Key result
Long noncoding RNAs offer promising next-generation therapeutic targets to mitigate glycation-associated diabetic nephropathy.
Why the study?
Endogenous glycation drives renal injury in diabetic nephropathy, but potent therapies remain limited, prompting exploration of long noncoding RNAs as potential therapeutic targets despite methodological constraints.
Long noncoding RNAs represent a promising future therapeutic target for mitigating glycation-associated diabetic nephropathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for lncRNA therapies in diabetic nephropathy; leaves open clinical translation pending prospective trials.
The glycation of various biomolecules is the root cause of many pathological conditions associated with diabetic nephropathy and end-stage kidney disease. Glycation imbalances metabolism and increases renal cell injury. Numerous therapeutic measures have narrowed down the adverse effects of endogenous glycation, but efficient and potent measures are miles away. Recent advances in the identification and characterization of noncoding RNAs, especially the long noncoding RNAs (lncRNAs), have opened a mammon of new biology to explore the mitigations for glycation-associated diabetic nephropathy. Furthermore, tissue-specific distribution and condition-specific expression make lncRNA a promising key for second-generation therapeutic interventions. Though the techniques to identify and exemplify noncoding RNAs are rapidly evolving, the lncRNA study encounters multiple methodological constraints. This review will discuss lncRNAs and their possible involvement in glycation and advanced glycation end products (AGEs) signaling pathways. We further highlight the possible approaches for lncRNA-based therapeutics and their working mechanism for perturbing glycation and conclude our review with lncRNAs biology-related future opportunities.
No takes yet. Share an insight, caveat, or question.
Durge et al. (2022) conducted a review in Diabetic nephropathy. Long noncoding RNAs (lncRNAs) was evaluated. Long noncoding RNAs offer a promising avenue for second-generation therapeutic interventions to mitigate glycation-associated diabetic nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: